ADP publishes the jobs data Wall Street watches every month, but its own payroll counts now tell a d

Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipe

Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors

HUTCHMED (China) said on ​Tuesday Anglo-Swedish ‌drugmaker AstraZeneca had filed ​an ​application wi

— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumor

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) L

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) L

[url="]Insperity, Inc.[/url] (NYSE: NSP), a leading provider of human resources and business perform

Lexicon Pharmaceuticals NASDAQ: LXRX said it has completed enrollment in its Phase III SONATA-HCM st

HUTCHMED (China) (NASDAQ:HCM) released quarterly financial results and hosted an earnings call on Th

Workday Named a Leader in Inaugural 2026 Gartner Magic Quadrant™ for Workforce Management Technol

HUTCHMED stock jumps on a $1.3B GSK deal for its cancer drug HMPL-A830. Learn the financial terms an

Gainers Cypherpunk Technologies (NASDAQ:CYPH) shares rose 30.4% to $2.19 during Thursday's regu

HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-Ch

HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology As

U.S. stocks rose Thursday; Summit Therapeutics jumped 10.1% after Phase III results, while Snowflake

Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market se

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City br

Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers an

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that its s

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday

GSK subsidiary ​GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay ‌a unit of HUTCHMED (Chin

— Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“

Workday Named a Leader in 2026 Gartner Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee E

AstraZeneca announced positive Phase 3 lung cancer trial results and earned EU approval for its Enhe

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces positive h

Findings build on the established success of the global SAFFRON and China SACHI trials, extending th

Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-a

Oracle Named a Leader in the 2026 Gartner Magic Quadrant™ for Supply Chain Management Suites PR N

Lexicon Pharmaceuticals (LXRX) is nearing multiple potential value-transforming events for sotaglifl

AstraZeneca reports mixed lung cancer trial data, highlighting successes for Tagrisso and Enhertu wh

First global Phase III trial to show significant progression-free and overall survival benefits in t

HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $0.09 per share. This is a 96.55 percen

Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and lowers

B of A Securities analyst Alec Stranahan maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and l

HUTCHMED reported positive Phase 2 data for fanregratinib in advanced ICC as China reviews the drug.

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile ——The

Companies granted approval by the China National Medical Products Administration ("NMPA") fo

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the New

B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and low

HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM; HKEX:13) tod

HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $2.62 per share which beat the analyst

First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced

HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a

NDA supported by results from a Phase II registration trial in China —— Second most common form of l

— First-in-human trial of candidate from the next-generation ATTC platform —— Simultaneous China and

— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with syner